Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer-Reference-Cited by-同舟云学术

Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer

Published:2024-08 Issue:2 Volume:86 Page:190-193
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Nickols Nicholas G.,Tsai Sonny,Kane Nathanael,Tran Samantha,Ghayouri Leila,Diaz-Perez Silvia,Thein May,Anderson-Berman Nancy,Eason Jeanie,Kishan Amar U.,Steinberg Michael L.,Reiter Robert E.,Lee Steve P.,Gin Greg E.,Kwon Robert,Chang Michael G.,Chao Hann-Hsiang,Solanki Abhiskek A.,Sexton Rachael,Lewis Michael,Lorentz William,Cheung Michael K.,Gage Diana L.,Duriseti Sai,Valle Luca,Berenji Gholam,Aronson William J.,Garraway Isla P.,Rettig Matthew B.

Funder

US Department of Veterans Affairs

Publisher

Elsevier BV

Reference5 articles.

1. Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials;Connor;Eur Urol Oncol,2020

2. A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer;O’Shaughnessy;Urology,2017

3. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer;Reyes;Med Oncol,2022

4. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol;Attard;Lancet Oncol,2023

5. Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer;McKay;J Urol,2021